Chlorambucil targets BRCA 1/2‐deficient tumours and counteracts PARP inhibitor resistance-Reference-Cited by-同舟云学术

Chlorambucil targets BRCA 1/2‐deficient tumours and counteracts PARP inhibitor resistance

Published:2019-05-24 Issue:7 Volume:11 Page:
ISSN:1757-4676
Container-title:EMBO Molecular Medicine
language:en
Short-container-title:EMBO Mol Med

Author:

Tacconi Eliana MC¹,Badie Sophie¹,De Gregoriis Giuliana¹,Reisländer Timo¹^ORCID,Lai Xianning¹,Porru Manuela²,Folio Cecilia¹,Moore John³,Kopp Arnaud⁴,Baguña Torres Júlia⁵,Sneddon Deborah⁵,Green Marcus³,Dedic Simon¹,Lee Jonathan W¹,Batra Ankita Sati⁶,Rueda Oscar M⁶,Bruna Alejandra⁶,Leonetti Carlo²,Caldas Carlos⁶,Cornelissen Bart⁵,Brino Laurent⁴,Ryan Anderson³,Biroccio Annamaria²^ORCID,Tarsounas Madalena¹^ORCID

Affiliation:

1. Genome Stability and Tumorigenesis Group Department of Oncology The CR‐UK/MRC Oxford Institute for Radiation Oncology University of Oxford Oxford UK

2. Area of Translational Research IRCCS Regina Elena National Cancer Institute Rome Italy

3. Lung Cancer Translational Science Research Group Department of Oncology The CR‐UK/MRC Oxford Institute for Radiation Oncology University of Oxford Oxford UK

4. Institut de Génétique et de Biologie Cellulaire et Moléculaire (IGBMC) Inserm U1258, CNRS (UMR 7104) Université de Strasbourg Illkirch France

5. Radiopharmaceuticals and Molecular Imaging Group Department of Oncology The CR‐UK/MRC Oxford Institute for Radiation Oncology University of Oxford Oxford UK

6. Department of Oncology Cancer Research UK Cambridge Institute University of Cambridge Cambridge UK

Funder

Cancer Research UK

Medical Research Council

University of Oxford

H2020 Marie Skłodowska-Curie Actions

Ministry of Health

Associazione Italiana per la Ricerca sul Cancro

Publisher

EMBO

Subject

Molecular Medicine